scholarly journals Combination of Allergic Asthma Symptom and Medication Scores in Allergen Immunotherapy Trials: A Proposal

2021 ◽  
pp. 1-3
Author(s):  
Raquel Caballero ◽  
Alicia Grau ◽  
Gracia Javaloyes ◽  
Sandra del Pozo ◽  
Miguel-Ángel León ◽  
...  
Keyword(s):  
Allergic Asthma ◽  
Asthma Symptom ◽  
Allergen Immunotherapy

scholarly journals Respiratory tract infections in children with allergic asthma on allergen immunotherapy during influenza season

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Yuyun Li ◽  
Dongming Wang ◽  
Lili Zhi ◽  
Yunmei Zhu ◽  
Lan Qiao ◽  
...  
Keyword(s):  
Respiratory Tract ◽  
Allergic Asthma ◽  
Respiratory Tract Infections ◽  
Allergen Immunotherapy ◽  
Clinical Symptoms ◽  
Influenza Season ◽  
The Body ◽  
History Of ◽  
Tract Infections ◽  
Stage 1

AbstractTo describle how respiratory tract infections (RTIs) that occurred in children with allergic asthma (AA) on allergen immunotherapy (AIT) during an influenza season. Data including clinical symptoms and treatment history of children (those with AA on AIT and their siblings under 14 years old), who suffered from RTIs during an influenza season (Dec 1st, 2019–Dec 31st, 2019), were collected (by face to face interview and medical records) and analyzed. Children on AIT were divided into 2 groups: stage 1 (dose increasing stage) and stage 2 (dose maintenance stage). Their siblings were enrolled as control. During the study period, 49 children with AA on AIT (33 patients in stage 1 and 16 patients in stage 2) as well as 49 children without AA ( their siblings ) were included. There were no significant differences in occurrences of RTIs among the three groups (p > 0.05). Compared with children in the other two groups, patients with RTIs in stage 2 had less duration of coughing and needed less medicine. Children on AIT with maintenance doses had fewer symptoms and recovered quickly when they were attacked by RTIs, which suggested that AIT with dose maintenance may enhance disease resistance of the body.

Asthma in adults: Principles of treatment

2019 ◽  
Vol 40 (6) ◽  
pp. 396-402 ◽  
Author(s):  
Jason H. Kwah ◽  
Anju T. Peters
Keyword(s):  
Allergic Asthma ◽  
Allergen Immunotherapy ◽  
Laryngopharyngeal Reflux ◽  
Normal Activity ◽  
Forced Expiratory Volume ◽  
Emergency Department Visits ◽  
Activity Level ◽  
Treatment Modalities ◽  
Allergen Specific Immunotherapy ◽  
Principles Of Treatment

The goals of treatment are prevention of fatalities, hospitalizations, and emergency department visits, along with achieving good long-term control of asthma, with reduction of symptoms, maintenance of normal activity level, prevention of exacerbations and accelerated loss of pulmonary function (forced expiratory volume in the first second of expiration [FEV1]), and avoidance of harm from therapies. Treatment is often initiated based on the severity of symptoms, physical examination findings, and, for some patients, the FEV1 or peak expiratory flow rates. Comorbidities such as gastroesophageal reflux disease and laryngopharyngeal reflux, rhinitis or rhinosinusitis, sleep apnea, recurrent infections, smoking, and substance abuse should be addressed. Two treatment modalities are indicated only for individuals with allergic asthma: allergen-specific immunotherapy (commonly known as allergy shots), and biologic therapies that target type-2 (T2) inflammation. Allergen immunotherapy is effective in decreasing symptoms and medication use in select patients with mild-to-moderate allergic asthma. In addition, patients who receive allergen immunotherapy for allergic rhinitis may have a decreased risk of developing asthma. Omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab are monoclonal antibodies that target T2 inflammation and are indicated for either moderate-to-severe or severe asthma. These have been well studied to improve asthma symptoms and have specific characteristics unique to each individual medication. A focus on adherence can be considered in choosing therapy because it is not clear which biologic to choose in T2 high asthma at this time.

scholarly journals Allergen immunotherapy for allergic asthma: a systematic overview of systematic reviews

2017 ◽  
Vol 7 (1) ◽  
Author(s):  
Felix Asamoah ◽  
Artemisia Kakourou ◽  
Sangeeta Dhami ◽  
Susanne Lau ◽  
Ioana Agache ◽  
...  
Keyword(s):  
Allergic Asthma ◽  
Systematic Reviews ◽  
Allergen Immunotherapy ◽  
Systematic Overview ◽  
Overview Of Systematic Reviews

scholarly journals SPECIFIC ALLERGEN IMMUNOTHERAPY RESULTS IN CHILDREN WITH ASTHMA DUE TO POLLENS ALLERGY. CLINICAL STUDY

2016 ◽  
Vol 63 (2) ◽  
pp. 178-182
Author(s):  
Georgeta Sinitchi ◽  
◽  
Aurica Rugina ◽  
Smaranda Diaconescu ◽  
◽  
...  
Keyword(s):  
Quality Of Life ◽  
Allergic Asthma ◽  
Grass Pollen ◽  
Allergen Immunotherapy ◽  
Life Assessment ◽  
Medical Needs ◽  
Careful Clinical Examination ◽  
Children With Asthma ◽  
Specific Allergen

Introduction. Specific allergen immunotherapy (STI) is the causal treatment of asthma. SIT gives a specific response to the changing LT response (deviation of the immune response), induction of anergy (decrease of LTh2), induces tolerance and modifies the inflammatory response. Pollen produces in our country seasonal allergic asthma in children and adults. Materials and methods. Our study was conducted using grass pollen extracts and comprised a total of 47 children with asthma, allergic to pollens, aged 5-14. Administration was seasonal (November to April), oral (sublingual solutions). It was indicated in the treatment of children with asthma and rhinitis with definite diagnosis where eviction was not possible. There have been previously detailed history and a careful clinical examination, skin prick tests to pollens with intense response, more elevated IgE, and spirometry confirming bronchospasm. Grass pollen extracts with initial low doses were used, gradually increasing the amount and concentration, and a gradual decrease, at a total of 6 months per year, with a duration of three years. Discussion. The evaluation was performed by clinical follow-up (symptom score and drug consumption), spirometry and by improving the quality of life assessment. There were no serious side effects during treatment. Conclusion. SIT in children with pollens allergic asthma is the causal therapeutic method; treating asthmatic children over 3 years old; reduces asthma symptoms to extinction; decreases other medical needs; improves quality of life of the child; no side effect were distinguished.

scholarly journals Impact of house dust mite-driven asthma on children’s school performance and activity

2021 ◽  
Author(s):  
Catalina Gómez ◽  
Judit Barrena ◽  
Vanesa García-Paz ◽  
Ana M. Plaza ◽  
Paula Crespo ◽  
...  
Keyword(s):  
Children And Adolescents ◽  
Allergic Asthma ◽  
House Dust ◽  
Allergen Immunotherapy ◽  
House Dust Mites ◽  
Dust Mites ◽  
Activity Impairment ◽  
Daily Lives ◽  
School Work ◽  
Clinical Benefits

AbstractEvidence regarding asthma’s impact on children’s daily lives is limited. This prospective and cross-sectional, observational, multicenter study assessed school/work and activity impairment in children and adolescents with allergic asthma and their caregivers and allergen immunotherapy (AIT) effects. Included patients were schooled children and adolescents (5 to 17 years) with allergic asthma due to house dust mites (HDM). Impairment of school/work (i.e., absenteeism and presenteeism) and activity was measured in patients and their caregivers using the Work Productivity Impairment Questionnaire plus Classroom Impairment Questions: Allergy Specific (WPAI + CIQ:AS). HDM allergic patients with school impairment received subcutaneous AIT with a MicroCrystalline Tyrosine-associated allergoid. WPAI + CIQ:AS and effectiveness variables were compared between baseline and 1-year post-AIT. Of the 113 patients included, 59 (52.2%) and 51 (45.1%) showed school and activity impairment, respectively, missing a mean (SD) of 37.6 (24.4) % and 42.6 (25.6) % of school and activity time, respectively. Twenty-six (23%) caregivers reported activity impairment and, of the 79 (69.9%) employed, 30 (38%) reported work impairment. Of the 65 patients with school/activities impairment, 41 (63.1%) received AIT, of which 21 (51.2%) completed 1 year of treatment. Effectiveness variables and WPAI + CIQ:AS significantly improved: Mean (SD) school impairment decreased from 39.7 (26.7) to 2.1 (7.1) % (p < 0.001) and activity impairment from 46.2 (34.6) to 1.4 (3.6) % (p < 0.001).Conclusion: Allergic asthma due to HDMs results in school/work and activity impairment in children and adolescents and their caregivers. One year of AIT provided clinical benefits and reduced school and activity impairment. What is Known:• Allergic asthma impairs children’s school performance and daily activities.• Allergen immunotherapy modifies allergic disease course and ameliorates its symptoms. What is New:• Asthma symptoms due to allergy to house dust mites impair children’s school attendance and productivity and daily activity and their caregivers’ work performance and daily lives.• Allergen immunotherapy with a house dust mite MicroCrystalline Tyrosine (MCT)-associated allergoid seems to provide clinical benefits, associated with decreased school and activity impairment, supporting it as an effective treatment option.

Sign in / Sign up

Export Citation Format

Share Document